SCHEMBL5340503

SCHEMBL5340503

O=C(CCCc1cccc2ccc(NC(=O)Nc3ccccc3)cc12)NC1CCCCC1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.53
EPHX1 P07099 6/20 0.49
RAB9A P51151 6/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
ICMT O60725 1/20 0.45
ALB P02768 1/20 0.45
NPC1 O15118 4/20 0.44
MEN1 O00255 2/20 0.44
LMNA P02545 2/20 0.44
KMT2A Q03164 2/20 0.44
TSHR P16473 1/20 0.44
HPGD P15428 1/20 0.44
GAA P10253 1/20 0.44
PKM P14618 1/20 0.43
ALOX15 P16050 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5337584 0.82 EPHX2 (0.54) EPHX2EPHX1RAB9ANPC1MEN1
SCHEMBL6076801 0.81 EPHX2 (0.53) EPHX2EPHX1RAB9ASMN1; SMN2MEN1
SCHEMBL5351385 0.81 EPHX2 (0.53) EPHX2EPHX1RAB9AMEN1KMT2A
SCHEMBL6075637 0.81 EPHX2 (0.53) EPHX2EPHX1RAB9ASMN1; SMN2NPC1
SCHEMBL5340392 0.81 EPHX2 (0.53) EPHX2EPHX1RAB9ASMN1; SMN2MEN1
SCHEMBL5348981 0.81 EPHX2 (0.53) EPHX2EPHX1RAB9ASMN1; SMN2MEN1
SCHEMBL6076741 0.81 EPHX2 (0.54) EPHX2EPHX1RAB9ASMN1; SMN2NPC1
SCHEMBL6076703 0.81 EPHX2 (0.54) EPHX2EPHX1RAB9ASMN1; SMN2MEN1
SCHEMBL8695744 0.79 MTNR1A (0.64) MEN1KMT2AHPGD
SCHEMBL5345810 0.78 MTNR1A (0.56) EPHX2EPHX1RAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7183318-B2 Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2007-02-27 US disclosed
EP-1077928-B1 NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SERVIER LAB (FR) 2005-12-07 EP disclosed
US-20040002490-A1 Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them LESIEUR DANIEL (FR) 2004-01-01 US disclosed
US-20040002491-A1 Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them LESIEUR DANIEL (FR) 2004-01-01 US disclosed
US-6605632-B1 Affinity for melatonin receptors LES LABORATOIRES SERVIER (FR) 2003-08-12 US disclosed
EP-1077928-A1 NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ADIR ET COMPAGNIE (FR) 2001-02-28 EP disclosed
WO-1999058496-A1 NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ADIR ET COMPAGNIE (FR) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002491-A1 Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them CYP4B1, CYP3A5, MC2R EPHX2 258/4885EPHX1 929/4885RAB9A 671/4885
US-20040002490-A1 Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them CYP3A5, CYP4B1, MC2R EPHX2 260/4885EPHX1 1045/4885RAB9A 697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.